Summary
The Kids B-LONG study was conducted to evaluate the pharmacokinetics, safety, and efficacy of recombinant human coagulation factor IX Fc fusion protein (rFIXFc) in pediatric subjects with hemophilia B. rFIXFc is considered safe and efficacious for prophylaxis and the control of acute bleeding in children age < 12 years.
- pediatric
- hemophilia B
- factor IX
- recombinant human coagulation factor IX Fc fusion protein
- hemophilia treatment
- hematology clinical trials
- © 2015 SAGE Publications
Tools
Recombinant Human Coagulation Factor IX Fc Fusion Protein Effective in Kids B-LONG Study
Permalink:
Table of contents
Cited By...
- No citing articles found.